209 related articles for article (PubMed ID: 22820988)
1. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.
Bandaranayake RM; Ungureanu D; Shan Y; Shaw DE; Silvennoinen O; Hubbard SR
Nat Struct Mol Biol; 2012 Aug; 19(8):754-9. PubMed ID: 22820988
[TBL] [Abstract][Full Text] [Related]
2. Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.
Wan X; Ma Y; McClendon CL; Huang LJ; Huang N
PLoS Comput Biol; 2013 Apr; 9(4):e1003022. PubMed ID: 23592968
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.
Varghese LN; Ungureanu D; Liau NP; Young SN; Laktyushin A; Hammaren H; Lucet IS; Nicola NA; Silvennoinen O; Babon JJ; Murphy JM
Biochem J; 2014 Mar; 458(2):395-405. PubMed ID: 24354892
[TBL] [Abstract][Full Text] [Related]
4. Differential biological activity of disease-associated JAK2 mutants.
Zou H; Yan D; Mohi G
FEBS Lett; 2011 Apr; 585(7):1007-13. PubMed ID: 21362419
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling.
Abraham BG; Haikarainen T; Vuorio J; Girych M; Virtanen AT; Kurttila A; Karathanasis C; Heilemann M; Sharma V; Vattulainen I; Silvennoinen O
Sci Adv; 2024 Mar; 10(10):eadl2097. PubMed ID: 38457493
[TBL] [Abstract][Full Text] [Related]
6. Identification of imidazo[1,2-
Moslin R; Gardner D; Santella J; Zhang Y; Duncia JV; Liu C; Lin J; Tokarski JS; Strnad J; Pedicord D; Chen J; Blat Y; Zupa-Fernandez A; Cheng L; Sun H; Chaudhry C; Huang C; D'Arienzo C; Sack JS; Muckelbauer JK; Chang C; Tredup J; Xie D; Aranibar N; Burke JR; Carter PH; Weinstein DS
Medchemcomm; 2017 Apr; 8(4):700-712. PubMed ID: 30108788
[TBL] [Abstract][Full Text] [Related]
7. A Catalytically Disabled Double Mutant of Src Tyrosine Kinase Can Be Stabilized into an Active-Like Conformation.
Meng Y; Ahuja LG; Kornev AP; Taylor SS; Roux B
J Mol Biol; 2018 Mar; 430(6):881-889. PubMed ID: 29410316
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations.
Wilmes S; Hafer M; Vuorio J; Tucker JA; Winkelmann H; Löchte S; Stanly TA; Pulgar Prieto KD; Poojari C; Sharma V; Richter CP; Kurre R; Hubbard SR; Garcia KC; Moraga I; Vattulainen I; Hitchcock IS; Piehler J
Science; 2020 Feb; 367(6478):643-652. PubMed ID: 32029621
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase.
Shan Y; Gnanasambandan K; Ungureanu D; Kim ET; Hammarén H; Yamashita K; Silvennoinen O; Shaw DE; Hubbard SR
Nat Struct Mol Biol; 2014 Jul; 21(7):579-84. PubMed ID: 24918548
[TBL] [Abstract][Full Text] [Related]
10. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
[TBL] [Abstract][Full Text] [Related]
11. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
[TBL] [Abstract][Full Text] [Related]
12. New insights into the structure and function of the pseudokinase domain in JAK2.
Silvennoinen O; Ungureanu D; Niranjan Y; Hammaren H; Bandaranayake R; Hubbard SR
Biochem Soc Trans; 2013 Aug; 41(4):1002-7. PubMed ID: 23863170
[TBL] [Abstract][Full Text] [Related]
13. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.
Lupardus PJ; Ultsch M; Wallweber H; Bir Kohli P; Johnson AR; Eigenbrot C
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8025-30. PubMed ID: 24843152
[TBL] [Abstract][Full Text] [Related]
14. The molecular regulation of Janus kinase (JAK) activation.
Babon JJ; Lucet IS; Murphy JM; Nicola NA; Varghese LN
Biochem J; 2014 Aug; 462(1):1-13. PubMed ID: 25057888
[TBL] [Abstract][Full Text] [Related]
15. Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases.
Toms AV; Deshpande A; McNally R; Jeong Y; Rogers JM; Kim CU; Gruner SM; Ficarro SB; Marto JA; Sattler M; Griffin JD; Eck MJ
Nat Struct Mol Biol; 2013 Oct; 20(10):1221-3. PubMed ID: 24013208
[TBL] [Abstract][Full Text] [Related]
16. Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.
Constantinescu SN; Leroy E; Gryshkova V; Pecquet C; Dusa A
Biochem Soc Trans; 2013 Aug; 41(4):1048-54. PubMed ID: 23863177
[TBL] [Abstract][Full Text] [Related]
17. Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.
Leroy E; Dusa A; Colau D; Motamedi A; Cahu X; Mouton C; Huang LJ; Shiau AK; Constantinescu SN
Biochem J; 2016 Jun; 473(11):1579-91. PubMed ID: 27029346
[TBL] [Abstract][Full Text] [Related]
18. Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles.
Rodriguez PL; Harada T; Christian DA; Pantano DA; Tsai RK; Discher DE
Science; 2013 Feb; 339(6122):971-5. PubMed ID: 23430657
[TBL] [Abstract][Full Text] [Related]
19. The protease activity of the paracaspase MALT1 is controlled by monoubiquitination.
Pelzer C; Cabalzar K; Wolf A; Gonzalez M; Lenz G; Thome M
Nat Immunol; 2013 Apr; 14(4):337-45. PubMed ID: 23416615
[TBL] [Abstract][Full Text] [Related]
20. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.
Losman JA; Looper RE; Koivunen P; Lee S; Schneider RK; McMahon C; Cowley GS; Root DE; Ebert BL; Kaelin WG
Science; 2013 Mar; 339(6127):1621-5. PubMed ID: 23393090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
